The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.
GlobalData on MSN
FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.
Live Science on MSN
IVF hormones could be delivered with painless 'microneedle' patch someday, early study hints
Scientists are developing a microneedle patch that they hope could someday simplify IVF hormone delivery. They've tested it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results